Dexcom’s new CEO is eyeing growth in the international market as a key strategy for 2026, fresh off the back of the company ...

Wondering whether DexCom's current share price lines up with its underlying worth, or if the market is missing something ...

While still a couple of years out, MD+DI gained some insights into Dexcom's next-generation sensor from an interview with the ...

In his inaugural J.P. Morgan Healthcare Conference speech, newly minted Dexcom CEO Jake Leach looked to ease concerns over ...

DexCom will release its fourth-quarter earnings next month, and analysts anticipate a double-digit bottom-line growth.

DexCom, Inc. (NASDAQ:DXCM) is one of the Best Fundamental Stocks to Buy According to Analysts. On January 12, the company ...

DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the ...

With Q3 behind us, let’s have a look at ResMed (NYSE:RMD) and its peers. Patient monitoring companies within the healthcare ...

Some of medtech's most innovative technologies were on display at the Consumer Electronics Show (CES) in Las Vegas this week.

Shares rose 6.4% to $71.73, putting the stock on pace for its highest close since September, according to Dow Jones Market ...

Investing.com -- Barclays downgraded DexCom and Insulet, two large-cap diabetes device makers, to Underweight as it expects rising competition in 2026 and 2027 to weigh on valuation multiples and ...

There are exciting advancements in patient standard of care thanks to continuous health monitoring technologies.